ADC Landscape
Sutro Biopharma
FRα · Ovarian, CBF/GLIS AML
Phase 2Antibody–Drug Conjugates
Target
FRα
Payload
Hemiasterlin (tubulin)
Payload class
Tubulin inhibitor
Linker
Cleavable
Indication
Ovarian, CBF/GLIS AML
Phase
Phase 2
Overview
Built on Sutro's cell-free, site-specific conjugation (XpressCF) for precise, homogeneous DAR. A differentiated FRα entrant with a non-standard payload.
Technology
Sutro Biopharma works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.